

## ASX RELEASE

### Update on timing of first patient dosing in Hepatitis C Trial

- **Several patients being screened for inclusion in current and subsequent cohorts**
- **Dosing to occur as soon as the first patient satisfactorily completes screening**

**Sydney Australia, 13 March 2014:** RNAi-based gene silencing therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today advised that several patients are undergoing screening at the Duke Clinical Research Unit in North Carolina for the company's TT-034 Phase I/IIa clinical trial in hepatitis C.

The precise timing of first patient dosing will be subject to a patient satisfactorily completing screening. Further to the ASX release on 18 February 2014, the first patient is now expected to be dosed within weeks.

**About Benitec Biopharma Limited:** Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com).

**About TT-034:** TT-034 is a potentially transformative therapeutic that is intended to provide a "one-shot-cure" for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance (a major problem for most hepatitis C drugs) by simultaneously silencing three separate highly conserved regions on the virus genome. Studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).

**For more information please contact:**

**Dr Peter French | Managing Director and Chief Executive Officer**  
Phone: +61 (02) 9555 6986 | [pfrench@benitec.com](mailto:pfrench@benitec.com) | [www.benitec.com](http://www.benitec.com)